Pupil Dilation for Treatment of IFIS

• Status: Completed
• Trial end date: 2020-09-25
• Target enrollment: 0
• Participant gender: All

Summary

A novel intervention for targeting the treatment of Intraoperative Floppy Iris Syndrome.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Denver Health and Hospital Authority
• Treatments: Brimonidine Tartrate; Ophthalmic Solutions

Criteria

Inclusion Criteria:

1. Adults (18 years old or greater) 3. History of having taken, or currently taking any systemic alpha blocker 2. Ability to consent themselves 3. Ability to apply eye drops themselves TID for 7 days

Exclusion Criteria:

1. Subjects with untreated hypertension or baseline BP >160

2. Subjects with Thyrotoxicosis

3. Pregnant women or women trying to conceive

4. Prisoners

5. Inability consent

6. Subjects with anatomical narrow angles or who have never had a dilated eye exam

7. Subjects currently prescribed brimonidine tartrate for glaucoma

8. Subjects who take topical or systemic alpha agonists

9. Patients who take monoamine oxidase (MAO) inhibitors

10. Patients with known severe cardiovascular disease